Recent News

• 08.06.2026 - Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
• 07.17.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 06.19.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 06.03.2026 - Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
• 06.01.2026 - Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
• 05.22.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 05.21.2026 - Iovance Biotherapeutics to Present at Upcoming Conference
• 05.07.2026 - Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
• 04.27.2026 - Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
• 04.17.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Recent Filings

• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 08.06.2026 - EX-99.1 EX-99.1
• 07.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.02.2026 - 8-K Current report
• 07.02.2026 - EX-99.1 EX-99.1
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities